- Home
- SABR vs ATXS Comparison
SABR vs ATXS Comparison
Compare SABR & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SABR | ATXS |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 627.9M | 732.4M |
| IPO Year | 2014 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SABR | ATXS |
|---|---|---|
| Price | $1.46 | $12.88 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 6 |
| Target Price | $4.12 | ★ $24.33 |
| AVG Volume (30 Days) | ★ 6.1M | 1.5M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.41 | N/A |
| Revenue | ★ $3,034,040,000.00 | $706,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.88 | N/A |
| P/E Ratio | $1.06 | ★ N/A |
| Revenue Growth | ★ 8.86 | N/A |
| 52 Week Low | $1.46 | $3.56 |
| 52 Week High | $4.63 | $13.29 |
Technical Indicators
Market Signals| Indicator | SABR | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | 33.50 | 60.37 |
| Support Level | $1.47 | $12.64 |
| Resistance Level | $1.56 | $13.00 |
| Average True Range (ATR) | 0.08 | 0.22 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 4.26 | 40.77 |
Price Performance
Historical ComparisonAbout SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2024 revenue, split between distribution (79% of segment sales) and airline IT solutions (21%) revenue. The company sold its growing hotel IT solutions division (9% of revenue) to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.